C A Lunn


Affiliation: Schering-Plough Research Institute
Country: USA


  1. Lunn C, Fine J, Rojas Triana A, Jackson J, Lavey B, Kozlowski J, et al. Cannabinoid CB(2)-selective inverse agonist protects against antigen-induced bone loss. Immunopharmacol Immunotoxicol. 2007;29:387-401 pubmed
    ..This result suggests that a cannabinoid CB(2)-selective inverse agonist may help ameliorate a particularly harmful property of this inflammatory joint disease...
  2. Lunn C, Fine J, Rojas Triana A, Jackson J, Fan X, Kung T, et al. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther. 2006;316:780-8 pubmed
  3. Lunn C. Updating the chemistry and biology of cannabinoid CB2 receptor-specific inverse agonists. Curr Top Med Chem. 2010;10:768-78 pubmed
    ..We will then discuss new biology associated with the cannabinoid CB(2) receptor for hints of how these compounds can best be utilized in vivo. ..
  4. Lunn C, Reich E, Bober L. Targeting the CB2 receptor for immune modulation. Expert Opin Ther Targets. 2006;10:653-63 pubmed